Novel Mettl3 Inhibitors And Use Thereof In Therapy

Abstract: The invention relates to a compound of Formula (I), or a tautomer stereoisomer, salt, solvate or N-oxide thereof, wherein A1 to A6, X, Y, R7a, R7b, R8a and R8b are as defined in the claims. The invention further concerns a pharmaceutical composition comprising same and a pharmaceutically acceptable carrier, and uses thereof as a drug in particular with an METTL3 inhibiting activity, advantageously for use in the treatment or prevention of a cancer, or an autoimmune, neurological, infectious or inflammatory disease.

Patent Information

Application #

Filing Date

29 October 2025

Publication Number

52/2025

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

NOVALIX

16 RUE D ANKARA QUAI DES ALPES 67000 STRASBOURG

AQEMIA

231 RUE SAINT-HONORÉ 75001 PARIS

Inventors

1. MEVELLEC, Laurence

19 rue du Rempart 27400 LOUVIERS

2. PREVET, Hugues

45 Route de Magny 27200 VERNON

3. SCHAMBEL, Philippe

35 chemin de lugan 81100 CASTRES

4. GEORGE, Nicolas

c/o AQEMIA 231 rue Saint-Honoré 75001 Paris

Specification

Documents

Application Documents

#	Name	Date
1	202517104478-STATEMENT OF UNDERTAKING (FORM 3) [29-10-2025(online)].pdf	2025-10-29
3	202517104478-Sequence Listing in PDF [29-10-2025(online)].pdf	2025-10-29
4	202517104478-REQUEST FOR EXAMINATION (FORM-18) [29-10-2025(online)].pdf	2025-10-29
5	202517104478-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [29-10-2025(online)].pdf	2025-10-29
6	202517104478-FORM 18 [29-10-2025(online)].pdf	2025-10-29
7	202517104478-FORM 1 [29-10-2025(online)].pdf	2025-10-29
8	202517104478-DECLARATION OF INVENTORSHIP (FORM 5) [29-10-2025(online)].pdf	2025-10-29
9	202517104478-COMPLETE SPECIFICATION [29-10-2025(online)].pdf	2025-10-29
10	202517104478-Proof of Right [02-01-2026(online)].pdf	2026-01-02